jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2022-14-1-69-77jofin-1310Research ArticleОригинальное исследованиеOriginal ResearchАнтитела к рецептор-связывающему домену спайкового белка SARS-COV-2: связь с возрастом, пневмонией, длительностью периода после COVID-19Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19КолосоваЕ. А.KolosovaE. A.

Колосова Евгения Андреевна – младший научный сотрудник лаборатории иммунохимии отдела биоинженерии; младший научный сотрудник Российско-Американского противоракового центра

Кольцово;Барнаул

Koltsovo; Barnaul

kurchanovaea@gmail.comШапроваО. Н.ShaprovaO. N.

Шапрова Ольга Николаевна – младший научный сотрудник лаборатории иммунохимии отдела биоинженерии 

Кольцово

Koltsovo

ngelya209@gmail.comНикулинаЮ. А.NikulinaYu. A.

Никулина Юлия Александровна – аспирант кафедры инфекционных болезней  

Барнаул

Barnaul

Julia_didenko91@gmail.comШаньшинД. В.ShanshinD. V.

Шаньшин Даниил Васильевич – младший научный сотрудник лаборатории иммунохимии отдела биоинженерии; младший научный сотрудник Российско-Американского противоракового центра 

Кольцово;Барнаул

Koltsovo; Barnaul

Dan6091154224@gmail.comНесмеяноваВ. С.NesmeyanovaV. S.

Несмеянова Валентина Сергеевна – стажер-исследователь лаборатории иммунохимии отдела биоинженерии 

Кольцово

Koltsovo

nesmeyanova_vs@vector.nsc.ruМеркульеваЮ. А.MerkulevaYu. A.

Меркульева Юлия Александровна – младший научный сотрудник лаборатории иммунохимии отдела биоинженерии 

Кольцово

Koltsovo

j.a.merkulyeva@gmail.comБеленькаяС. В.BelenkayaS. V.

Беленькая Светлана Валерьевна – младший научный сотрудник лаборатории иммунохимии отдела биоинженерии 

Кольцово

Koltsovo

belenkaya.sveta@gmail.comИсаеваА. А.IsaevaA. A.

Исаева Анастасия Александровна – младший научный сотрудник лаборатории иммунохимии отдела биоинженерии 

Кольцово

Koltsovo

anastasya_isaeva_1993@mail.ruЩербаковД. Н.ShcherbakovD. N.

Щербаков Дмитрий Николаевич – ведущий научный сотрудник, заведующий лабораторией иммунохимии отдела биоинженерии; ведущий научный сотрудник Российско-Американского противоракового центра, к.б.н. 

Кольцово;Барнаул

Koltsovo; Barnaul

dnshcherbakov@gmail.comЕльчаниноваС. А.ElchaninovaS. A.

Ельчанинова Светлана Александровна – профессор кафедры биохимии и клинической лабораторной диагностики, д.б.н., профессор 

Барнаул

Barnaul

saelch@mail.ruНиконороваМ. А.NikonorovaM. A.

Никонорова Марина Анатольевна – профессор кафедры инфекционных болезней, д.м.н. 

Барнаул

Barnaul

ma.nikulina@mail.ruГосударственный научный центр вирусологии и биотехнологии «Вектор»; Алтайский государственный университетРоссияThe State Scientific Center of Virology and Biotechnology «Vector»; Altai State UniversityRussian FederationГосударственный научный центр вирусологии и биотехнологии «Вектор»РоссияThe State Scientific Center of Virology and Biotechnology «Vector»Russian FederationАлтайский государственный медицинский университетРоссияAltai State Medical UniversityRussian Federation2022050420221416977Copyright © Колосова Е.А., Шапрова О.Н., Никулина Ю.А., Шаньшин Д.В., Несмеянова В.С., Меркульева Ю.А., Беленькая С.В., Исаева А.А., Щербаков Д.Н., Ельчанинова С.А., Никонорова М.А., 20222022Колосова Е.А., Шапрова О.Н., Никулина Ю.А., Шаньшин Д.В., Несмеянова В.С., Меркульева Ю.А., Беленькая С.В., Исаева А.А., Щербаков Д.Н., Ельчанинова С.А., Никонорова М.А.Kolosova E.A., Shaprova O.N., Nikulina Y.A., Shanshin D.V., Nesmeyanova V.S., Merkuleva Y.A., Belenkaya S.V., Isaeva A.A., Shcherbakov D.N., Elchaninova S.A., Nikonorova M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1310

Несмотря на быстрое накопление фактов о гуморальном иммунном ответе при COVID-19, пока нет доказательных ответов на вопросы о факторах, влияющих на уровень и длительность периода обнаружения антител к SARS-CoV-2 в крови.

Цель

Цель: оценить распространенность наличия, клинические и демографические ассоциации антител IgG к RBD спайкового белка SARS-CoV-2 в разные сроки после COVID-19.

Материалы и методы

Материалы и методы. В одномоментном обсервационном исследовании приняли участие жители Алтайского края России, европеоиды, в возрасте от 20 до 93 лет, переболевшие COVID-19 в период с мая 2020 г. по февраль 2021 г. (n=314). Уровень антител в крови измеряли через 1–14 месяцев от начала клинической манифестации COVID-19 методом иммуноферментного анализа.

Результаты

Результаты. Антитела IgG к RBD спайкового белка SARS-CoV-2 обнаружены у 86,9% участников исследования. Не выявлено зависимости титра антител от давности COVID-19. Титр антител положительно коррелировал с осложнением пневмонией COVID-19 и объемом поражений легочной ткани. Наличие пневмонии COVID-19 и объем поражений легочной ткани положительно связаны с возрастом. Возраст положительно коррелировал с титром антител независимо от наличия пневмонии COVID-19 в анамнезе.

Заключение

Заключение. Антитела IgG к RBD спайкового белка SARS-CoV-2 имеются у большей части переболевших COVID-19. Титр этих антител у взрослых зависит от возраста, осложнения пневмонией COVID-19 и может сохраняться до 14 месяцев после появления первых симптомов инфекции.

Despite the rapid accumulation of facts about the humoral immune response in COVID-19, there are still no evidencebased answers to questions about the factors influencing the level and duration of the detection period of antibodies to SARS-CoV-2 in the blood.

Objective

Objective: To assess the prevalence, clinical and demographic associations of IgG antibodies to RBD of the SARSCoV-2 spike protein at different times after COVID-19.

Materials and methods

Materials and methods. Residents of the Altai region of Russia, Caucasians aged 20-93 years, who had COVID-19 from May 2020 to February 2021 (n = 314), took part in a onetime observational study. The level of antibodies in the blood was measured by enzyme-linked immunosorbent assay 1-14 months after the onset of the clinical manifestation of COVID-19.

Results

Results. Anti-RBD IgG antibodies of the SARS-CoV-2 spike protein were detected in 86.9% of the study participants. The dependence of the antibody titer on the duration of the period after COVID-19 was not revealed. The antibody titer was positively correlated with the complication of COVID-19 pneumonia and the volume of lung tissue lesions. The presence of pneumonia COVID-19 and the volume of lung tissue lesions are positively associated with age. Age positively correlated with antibody titer regardless of the pneumonia COVID-19 in the anamnesis.

Conclusion

Conclusion. IgG antibodies to RBD of the SARS-CoV-2 spike protein are present in most of the COVID-19 patients. The titer of these antibodies in adults depends on age, complications of pneumonia COVID-19, and probably persists up to 14 months after the first symptoms of infection appear.

COVID-19антителарецепторсвязывающий доменS-белокSARS-CoV-2возрастпневмонияCOVID-19antibodiesreceptor-binding domainS-proteinSARS-CoV-2agepneumoniaРабота выполнена при поддержке государственного задания (№ FZMW-2020-0007) и Стипендии президента Российской Федерации (СП5107.2021.4)ReferencesLotfi R, Kalmarzi RN, Roghani S.A. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Immunol Res. 2021;69:213–224. https://doi.org/10.1007/s12026-021-09198-0Lotfi R, Kalmarzi RN, Roghani S.A. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Immunol Res. 2021;69:213–224. https://doi.org/10.1007/s12026-021-09198-0Byrnes JR, Zhou XX, Lui I, et al. Competitive SARS-CoV-2 serology reveals most antibodies targeting the spike receptorbinding domain compete for ACE2 binding. mSphere. 2020 Sep 16;5(5):e00802-20. https://doi.org/10.1128/mSphere.00802-20Byrnes JR, Zhou XX, Lui I, et al. Competitive SARS-CoV-2 serology reveals most antibodies targeting the spike receptorbinding domain compete for ACE2 binding. mSphere. 2020 Sep 16;5(5):e00802-20. https://doi.org/10.1128/mSphere.00802-20Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem.1951;193:265–275.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem.1951;193:265–275.Ilyicheva T, Durymanov A, Susloparov I, et al. Fatal Cases of Seasonal Influenza in Russia in 2015-2016. PLoS One. 2016 Oct 24;11(10):e0165332. https://dx.doi.org/10.1371%2Fjournal.pone.0165332Ilyicheva T, Durymanov A, Susloparov I, et al. Fatal Cases of Seasonal Influenza in Russia in 2015-2016. PLoS One. 2016 Oct 24;11(10):e0165332. https://dx.doi.org/10.1371%2Fjournal.pone.0165332Schoof M, Faust B, Saunders RA, Sangwan S, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473–1479. http://dx.doi.org/10.1126/science.abe3255Schoof M, Faust B, Saunders RA, Sangwan S, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473–1479. http://dx.doi.org/10.1126/science.abe3255Kazachinskaia E, Chepurnov A, Shcherbakov D, et al. IgG Study of Blood Sera of Patients with COVID-19. Pathogens. 2021; 10(11):1421. https://doi.org/10.3390/pathogens10111421Kazachinskaia E, Chepurnov A, Shcherbakov D, et al. IgG Study of Blood Sera of Patients with COVID-19. Pathogens. 2021; 10(11):1421. https://doi.org/10.3390/pathogens10111421Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2020 Dec 31;15(12):e0244126. https://doi.org/10.1371/journal.pone.0244126Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2020 Dec 31;15(12):e0244126. https://doi.org/10.1371/journal.pone.0244126Wilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26:1070–6. https://doi.org/10.1038/s41591-020-0944-yWilk AJ, Rustagi A, Zhao NQ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26:1070–6. https://doi.org/10.1038/s41591-020-0944-yGallais F, Gantner P, Bruel T, et al. Anti-SARS-CoV-2 Antibodies persist for up to 13 months and reduce risk of reinfection. medRxiv. 2021 05.07.21256823. https://doi.org/10.1101/2021.05.07.21256823Gallais F, Gantner P, Bruel T, et al. Anti-SARS-CoV-2 Antibodies persist for up to 13 months and reduce risk of reinfection. medRxiv. 2021 05.07.21256823. https://doi.org/10.1101/2021.05.07.21256823Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci;2021:36:e54. https://doi.org/10.3346/jkms.2021.36.e54Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci;2021:36:e54. https://doi.org/10.3346/jkms.2021.36.e54Yao L, Wang GL, Shen Y, et al. Persistence of antibody and cellular immune responses in COVID-19 patients over nine months after infection. J Infect Dis. 2021:jiab255. https://doi.org/10.1093/infdis/jiab255Yao L, Wang GL, Shen Y, et al. Persistence of antibody and cellular immune responses in COVID-19 patients over nine months after infection. J Infect Dis. 2021:jiab255. https://doi.org/10.1093/infdis/jiab255Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639-644. https://doi.org/10.1038/s41586-021-03207-wGaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639-644. https://doi.org/10.1038/s41586-021-03207-wXiang T, Liang B, Fang Y, et al. Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset. Front Immunol. 2021 Jun 16;12:708523. https://doi.org/10.3389/fimmu.2021.708523Xiang T, Liang B, Fang Y, et al. Declining levels of neutralizing antibodies against SARS-CoV-2 in convalescent COVID-19 patients one year post symptom onset. Front Immunol. 2021 Jun 16;12:708523. https://doi.org/10.3389/fimmu.2021.708523Pr vost J, Gasser R, Beaudoin-Bussi res G, et al. Crosssectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Rep Med. 2020 Oct 20;1(7):100126. https://doi.org/10.1016/j.xcrm.2020.100126Pr vost J, Gasser R, Beaudoin-Bussi res G, et al. Crosssectional evaluation of humoral responses against SARS-CoV-2 spike. Cell Rep Med. 2020 Oct 20;1(7):100126. https://doi.org/10.1016/j.xcrm.2020.100126Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 Jul;595(7867):426-431. https://doi.org/10.1038/s41586-021-03696-9Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 Jul;595(7867):426-431. https://doi.org/10.1038/s41586-021-03696-9Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. https://doi.org/10.1126/science.abf4063Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. https://doi.org/10.1126/science.abf4063Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccineinduced sera. Cell. 2021;S0092–8674:00226–9. https://doi.org/10.1016/j.cell.2021.02.037Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccineinduced sera. Cell. 2021;S0092–8674:00226–9. https://doi.org/10.1016/j.cell.2021.02.037Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity. 2021;54:205–10. https://doi.org/10.1016/j.immuni.2021.01.014Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity. 2021;54:205–10. https://doi.org/10.1016/j.immuni.2021.01.014Terpos E, Stellas D, Rosati M, et al. SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. Eur J Intern Med. 2021 Jul;89:87-96. https://doi.org/10.1016/j.ejim.2021.05.010Terpos E, Stellas D, Rosati M, et al. SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. Eur J Intern Med. 2021 Jul;89:87-96. https://doi.org/10.1016/j.ejim.2021.05.010Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 Infection severity is linked to superior humoral immunity against the spike. mBio. 2021 Jan;12(1):e02940-20. https://dx.doi.org/10.1128%2FmBio.02940-20Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 Infection severity is linked to superior humoral immunity against the spike. mBio. 2021 Jan;12(1):e02940-20. https://dx.doi.org/10.1128%2FmBio.02940-20Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021 Feb;18(2):318-327. https://doi.org/10.1038/s41423-020-00588-2Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021 Feb;18(2):318-327. https://doi.org/10.1038/s41423-020-00588-2Atyeo C, Fischinger S, Zohar T, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020 Sep;53:524–532.e4. https://dx.doi.org/10.1016%2Fj.immuni.2020.07.020Atyeo C, Fischinger S, Zohar T, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020 Sep;53:524–532.e4. https://dx.doi.org/10.1016%2Fj.immuni.2020.07.020Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. mBio. 2021 Jan-Feb;12(1):e02940-20. https://dx.doi.org/10.1128%2FmBio.02940-20Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. mBio. 2021 Jan-Feb;12(1):e02940-20. https://dx.doi.org/10.1128%2FmBio.02940-20Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020 Jun;584:437–442. https://dx.doi.org/10.1038%2Fs41586-020-2456-9Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020 Jun;584:437–442. https://dx.doi.org/10.1038%2Fs41586-020-2456-9Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARScoronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. https://doi.org/10.1101/2020.01.31.929042Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARScoronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020. https://doi.org/10.1101/2020.01.31.929042Ortega, N., Ribes, M., Vidal, M. et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun 2021;12: 4740. https://doi.org/10.1038/s41467-021-24979-9Ortega, N., Ribes, M., Vidal, M. et al. Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nat Commun 2021;12: 4740. https://doi.org/10.1038/s41467-021-24979-9Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. mBio. 2021 Jan;12(1): e02940-20. https://doi.org/10.1128/mBio.02940-20Guthmiller JJ, Stovicek O, Wang J, et al. SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike. mBio. 2021 Jan;12(1): e02940-20. https://doi.org/10.1128/mBio.02940-20

The authors declare that there are no conflicts of interest present.